Key points are not available for this paper at this time.
Identifying patients with cancer who are most at risk for VTE is essential to better target thromboprophylaxis, with the eventual goal of reducing the burden as well as the consequences of VTE for patients with cancer.
Khorana et al. (Tue,) studied this question.